SK Biopharm Reports Q2 Revenue of 2.1 Billion KRW and Operating Loss of 57.8 Billion KRW
[Asia Economy Reporter Cho Hyun-ui] SK Biopharm announced on the 14th that its consolidated sales for the second quarter of this year amounted to 2.1 billion KRW, with an operating loss of 57.8 billion KRW.
Compared to the previous quarter, sales decreased by 47.4%, while the operating loss improved by 11.2% due to a reduction in selling and administrative expenses.
Hot Picks Today
!["It Has Now Crossed Borders": No Vaccine or Treatment as Bundibugyo Ebola Variant Spreads [Reading Science]](https://cwcontent.asiae.co.kr/asiaresize/93/2026052019230771274_1779272587.jpg)
"It Has Now Crossed Borders": No Vaccine or Treatment as Bundibugyo Ebola Variant Spreads [Reading Science]
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
- "Am I Really in the Top 30%?" and "Worried About My Girlfriend in the Bottom 70%"... Buzz Over High Oil Price Relief Fund
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
SK Biopharm explained that there were no products launched last year, so the comparison was made with the previous quarter. Compared to the same period last year, sales in the second quarter of this year decreased by 68.3%, and operating profit turned into a loss.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
